Novartis has submitted NVA237, the company’s new treatment for chronic obstructive pulmonary disease, for approval in Japan.

The drug, which was submitted for European approval in September 2011 under the brand name Seebri Breezhaler, is a long-acting muscarinic antagonist designed to be taken once-daily.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Novartis originally licensed the drug from Japanese pharmaceutical company Sosei and UK-based Vectura in April 2005.

Novartis last week signed Eisai as a co-promoter of the drug should it receive Japanese approval.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now